公开(公告)号：US20240174639A1

公开(公告)日：2024-05-30

申请号：US18279796

申请日：2022-03-02

申请人： King's College London

发明人： Peter A. McNaughton ,  Karen Williams ,  Sue Cramp ,  Alan Naylor

IPC分类号： C07D401/14 ,  A61K31/4439 ,  A61K31/444 ,  A61P27/00 ,  A61P29/00 ,  C07D401/10 ,  C07D471/04

CPC分类号： C07D401/14 ,  A61K31/4439 ,  A61K31/444 ,  A61P27/00 ,  A61P29/00 ,  C07D401/10 ,  C07D471/04

摘要： Compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the substituents are defined in the specification. The compounds are hyperpolarisation activated cyclic-nucleotide modulated ion channel 2 (HCN2) inhibitors. Also disclosed are pharmaceutical compositions comprising the compounds, and the use of the compounds for the treatment or prevention of medical conditions mediated by HCN2, including neuropathic pain.

公开(公告)号：US20240092775A1

公开(公告)日：2024-03-21

申请号：US18203776

申请日：2023-05-31

申请人： Ocu Terra Therapeutics, Inc.

发明人： Ben C. ASKEW ,  Takeru FURUYA

IPC分类号： C07D471/04 ,  A61P1/00 ,  A61P27/00

CPC分类号： C07D471/04 ,  A61P1/00 ,  A61P27/00

摘要： The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating fibrosis, macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.

公开(公告)号：US11826387B2

公开(公告)日：2023-11-28

申请号：US17369075

申请日：2021-07-07

申请人： PROTOKINETIX INC.

发明人： Lachlan Grant Young

IPC分类号： A61K35/30 ,  A61K31/16 ,  A61K31/164 ,  C07K14/00 ,  C07K5/08 ,  C07K9/00 ,  A61K31/335 ,  A61P27/00 ,  A61K38/14 ,  C07K5/10

CPC分类号： A61K35/30 ,  A61K31/16 ,  A61K31/164 ,  A61K31/335 ,  A61K38/14 ,  A61P27/00 ,  C07K5/08 ,  C07K5/0827 ,  C07K9/001 ,  C07K14/00 ,  C07K5/1027

摘要： The present disclosure relates to an in vitro method for enhancing engraftment of neurosensory precursor cell comprising the step of contacting an isolated neurosensory precursor cell prior to a transplantation in a subject in need thereof, with a gem-difluorinated C-glycopeptide compound of general formula I, or a pharmaceutically acceptable base, addition salt with an acid, hydrate or solvate thereof:

公开(公告)号：US20230373932A1

公开(公告)日：2023-11-23

申请号：US18085466

申请日：2022-12-20

申请人： Japan Tobacco Inc.

发明人： Masahiro YOKOTA ,  Taku IKENOGAMI ,  Eiichi WATANABE ,  Noriyoshi SEKI ,  Takayuki SAKAI ,  Shingo FUJIOKA ,  Makoto SHIOZAKI ,  Katsunori SUWA ,  Yosuke OGOSHI ,  Masato NOGUCHI ,  Katsuya MAEDA

IPC分类号： C07D239/22 ,  A61P37/00 ,  C07D413/04 ,  A61P43/00 ,  A61K31/505 ,  A61P17/00 ,  C07D401/04 ,  A61K31/695 ,  A61P27/00 ,  A61K31/506 ,  C07C265/02 ,  C07C275/06 ,  C07F7/08 ,  A61P25/00 ,  C07F7/12 ,  A61P3/00 ,  C07D403/04 ,  C07D405/04 ,  C07D405/10 ,  A61P29/00

CPC分类号： C07D239/22 ,  A61P37/00 ,  C07D413/04 ,  A61P43/00 ,  A61K31/505 ,  A61P17/00 ,  C07D401/04 ,  A61K31/695 ,  A61P27/00 ,  A61K31/506 ,  C07C265/02 ,  C07C275/06 ,  C07F7/0812 ,  A61P25/00 ,  C07F7/12 ,  A61P3/00 ,  C07D403/04 ,  C07D405/04 ,  C07D405/10 ,  A61P29/00

摘要： A compound of Formula [I] or a pharmaceutically acceptable salt thereof:




wherein each symbol is defined as in the specification.

公开(公告)号：US11753377B2

公开(公告)日：2023-09-12

申请号：US18000685

申请日：2021-06-17

申请人： ZHUHAI UNITED LABORATORIES CO., LTD.

发明人： Xiaolin Li ,  Chong Su ,  Zhi Luo ,  Fei Hao ,  Peng Li ,  Haiying He ,  Jian Li ,  Shuhui Chen

IPC分类号： C07D213/73 ,  A61P27/00

CPC分类号： C07D213/73 ,  A61P27/00 ,  C07B2200/13

摘要： A crystal form (such as formula I) of a 2-methyl-2-propanol and amino-substituted aryl compound and a preparation method therefor. Also provided is an application of the crystal form in the preparation of a medicine for treating related diseases.

公开(公告)号：US20230226082A1

公开(公告)日：2023-07-20

申请号：US17985097

申请日：2022-11-10

申请人： Bioved Pharmaceuticals, Inc.

发明人： Deepa Chitre ,  Debendranath Dey ,  Satej R Nadkarni

IPC分类号： A61K31/585 ,  A61K31/19 ,  A61K31/12 ,  A61K36/9068 ,  A61K36/9066 ,  A61K36/324 ,  A61K36/81 ,  A61K31/675 ,  A61K31/4025 ,  A61K31/375 ,  A61K33/30 ,  A61K31/198 ,  A61K9/20 ,  A61K9/16 ,  A61P31/14 ,  A61P27/00

CPC分类号： A61K31/585 ,  A61K31/19 ,  A61K31/12 ,  A61K36/9068 ,  A61K36/9066 ,  A61K36/324 ,  A61K36/81 ,  A61K31/675 ,  A61K31/4025 ,  A61K31/375 ,  A61K33/30 ,  A61K31/198 ,  A61K9/2059 ,  A61K9/2009 ,  A61K9/2027 ,  A61K9/1611 ,  A61K9/1652 ,  A61P31/14 ,  A61P27/00 ,  A61K2236/333 ,  A61K2236/53

摘要： Methods and formulations for treating and preventing LONG COVID sequelae are provided. An example method treats loss of smell and taste from SARS-CoV-2 infection, including assessing the patient, administering a composition with dosage between 1750-3600 mg per day, wherein the composition comprises a mixture of at least a withanolide-A, a boswellic acid, a [6]-gingerol, and a curcuminoid. Another example method treats memory loss or brain fog from SARS-CoV-2 infection, including assessing the patient, and administering a regenerative and neuroprotective composition comprising a mixture of withanoside VI, withanolide A, a Boswellia serrata plant, a Zingiber officinale rhizome, and a Curcuma longa rhizome. The compositions were found effective, achieving statistical significance in a multi-center, randomized, double-blind, placebo-controlled phase III clinical trial.

公开(公告)号：US20230047296A1

公开(公告)日：2023-02-16

申请号：US17495115

申请日：2021-10-06

申请人： GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED ,  ASTEX THERAPEUTICS LIMITED

发明人： Jeffrey K. KERNS ,  James Callahan ,  Hongxing Yan ,  Thomas Daniel Heightman ,  Charlotte Mary Griffiths-Jones ,  Alison Jo-Anne Woolford ,  Tindy Li ,  Ami Lakdawala Shah ,  Roderick S. Davis ,  David Norton ,  Jeffrey Charles Boehm ,  Paris L. Hamilton ,  Nicole Cathleen Goodwin ,  Yun Jin

IPC分类号： C07D403/10 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D401/10 ,  C07D403/14 ,  C07D413/10 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  C07D267/14 ,  C07D249/18 ,  C07D233/60 ,  C07D487/08 ,  C07D451/02 ,  A61P9/00 ,  A61P25/00 ,  A61P11/00 ,  A61P27/00 ,  A61P35/00 ,  A61P37/00 ,  C07D233/64 ,  C07D255/04 ,  C07D273/01 ,  C07D405/10

摘要： The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.

公开(公告)号：US20220389450A1

公开(公告)日：2022-12-08

申请号：US17742924

申请日：2022-05-12

申请人： FONDAZIONE TELETHON

发明人： Alberto AURICCHIO ,  Fabio DELL'AQUILA ,  Ivana TRAPANI ,  Rita FERLA

IPC分类号： C12N15/86 ,  A61P27/00 ,  C07K14/47

摘要： A vector system for expressing a transgene in a cell, the vector system comprising a first vector and a second vector, wherein: (a) the first vector comprises in a 5′ to 3′ direction: a promoter; an intron; a 5′ end portion of the transgene coding sequence (CDS); a splice donor sequence; and a first recombinogenic region; (b) the second vector comprises in a 5′ to 3′ direction: a second recombinogenic region; a splice acceptor sequence; and a 3′ end portion of the transgene CDS; wherein the 5′ end portion and the 3′ end portion together constitute the transgene CDS, and wherein the intron is not capable of homologous recombination with the splice donor sequence to excise the 5′ end portion of the transgene CDS.

公开(公告)号：US20220333065A1

公开(公告)日：2022-10-20

申请号：US17621068

申请日：2020-06-19

申请人： CENTRE D'ETUDE DES CELLULES SOUCHES (CECS)

发明人： Christelle MONVILLE ,  Florian REGENT ,  Lise MORIZUR ,  Karim BEN M'BAREK

IPC分类号： C12N5/0793 ,  A61P27/00

摘要： Disclosed are methods for preparing retinal pigment epithelium (RPE) cells from pluripotent stem cells (PSCs). More particularly, it represents an automated method that combines in a sequential manner three differentiating agents to direct the differentiation of human PSCs into RPE cells.

公开(公告)号：US11472814B2

公开(公告)日：2022-10-18

申请号：US16619625

申请日：2018-06-05

申请人： SignalRx Pharmaceuticals, Inc.

发明人： Guillermo A. Morales ,  Joseph R. Garlich ,  Donald L. Durden

IPC分类号： C07D495/04 ,  C07D493/04 ,  C07D519/00 ,  A61P27/00 ,  A61P29/00 ,  A61P35/04 ,  A61P37/00 ,  A61P35/00 ,  A61K45/06

摘要： The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral, bacterial or fungal infection, atherosclerosis, Type 1 or 2 diabetes, obesity, inflammatory disease, and/or SYK-associated disorder including by modulating biological processes through the inhibition of SYK alone, or in combination with inhibition of one or more of PI3 kinase including PI3K-gamma isoform, BET bromodomain proteins, CDK 4/6, and checkpoint proteins, comprising the administration of a compound(s) of Formula I-V (or pharmaceutically acceptable salts thereof) as defined herein.